Reference |
Title |
Study Design |
Bastos et al. 2007
|
"Histologic analysis of zafirlukast's effect on capsule formation around silicone implants".
|
Animals: 32 adult female Wistar rats. Groups: 3 groups that received both smooth and textured surface silicone mini-implant. Intervention: Intraperitoneal treatment with either vehicle or zafirlukast (1.25 or 5 mg/kg/day; for 90 days). Follow up: 90 days. Capsular evaluation: Histological (HE, trichrome and picrosirius red stain), and immunohistochemistry (anti-α-SMA antibody) analyses. |
Bastos et al. 2012
|
"Effect of zafirlukast on capsular contracture around silicone implants in rats".
|
Animals: 40 adult female Wistar rats. Groups: 4 groups that received both smooth and textured surface silicone mini-implant. Intervention: Intraperitoneal treatment with either zafirlukast (1.25 mg/kg/day; during 90 days) or vehicle. Follow up: 90 days. Capsular evaluation: Intra-implant pressure measurement. |
Bergmann et al. 2014
|
"The effect of a bacterial contamination on the formation of capsular contracture with polyurethane breast implants in comparison with textured silicone implants: an animal study".
|
Animals: 80 adult female Wistar rats. Groups: 4 groups that received either textured surface or PU-coated silicone mini-implant. Intervention: Implant inoculation with vehicle or a standard volume of Staphylococcus epidermidis. Follow up: 60 days. Capsular evaluation: Histological (HE, trichrome, naphthol-ASD-acetatesterase and picrosirius red stain), immunohistochemistry (anti-CD3, anti-CD138, anti-Lysozyme, anti-Pax5 and anti-α-SMA antibodies), and microbiological analyses. |
Cardenas-Camarena et al. 2005 |
"Electrostimulation: uses and applications for periprosthetic capsular contracture: experimental model".
|
Animals: 40 adult female Wistar rats; Groups: 10 groups that received both smooth and textured surface silicone min-implant. Intervention: Different protocols of local electrostimulation from the 3rd to the 15th postoperative day. Follow up: 16 days; Capsular evaluation: Histological (HE) analyses. |
Gancedo et al. 2008
|
"Pirfenidone prevents capsular contracture after mammary implantation".
|
Animals: 20 adult female Wistar rats. Groups: 2 groups that received both smooth and textured surface silicone mini-implant. Intervention: Intraperitoneal treatment with vehicle or Pirfenidone (PFD) (200 mg/Kg/day, for 60 days). Follow up: 60 days. Capsular evaluation: Histological (HE, trichrome, picrosirius red stain), immunohistochemistry (anti-TGF-β1, anti-α-SMA antibodies), and real-time PCR (TGF-β and collagen αI) analyses. |
Mendes et al. 2008
|
"Histological study on acute inflammatory reaction to polyurethane-coated silicone implants in rats".
|
Animals: 35 adult female Wistar rats. Groups: 7 groups that received PU-coated silicone mini-implant. Intervention: Contamination of implant cavity with 101, 103, or 105 bacteria/mL with implant immersions in anti-microbial solution or saline. Follow up: 30 days. Capsular evaluation: Histological (HE and picrosirius red stain) analyses. |
Vieira et al. 2010
|
"Vascular endothelial growth factor overexpression positively modulates the characteristics of periprosthetic tissue of polyurethane-coated silicone breast implant in rats".
|
Animals: 34 adult female Wistar rats. Groups: 4 groups that received textured surface or PU-coated silicone mini-implant. Intervention: no intervention. Follow up: 30 and 60 days. Capsular evaluation: Histological (HE, trichrome, picrosirius red stain), immunohistochemistry (anti-VEGF, anti-TGF-β1, anti-α-SMA, and anti-MPX antibodies) analysis. |
Zimman et al. 2007
|
"The effects of angiotensin-converting-enzyme inhibitors on the fibrous envelope around mammary implants".
|
Animals: 24 adult female Wistar rats. Groups: 4 groups that received either smooth or textured surface silicone mini-implants. Intervention: angiotensin-converting enzyme inhibitor enalapril administered in drinking water, ad libitum. Follow up: 90 days. Capsular evaluation: Histological (HE, trichrome, picrosirius red stain), and immunohistochemistry (anti-TGF-β1 and anti-collagen type III antibodies) analysis. |